Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | HTR7 | P34969 | 2/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152151 | 1.00 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL7526992 | 0.98 | SIRT6 (1.00) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL336262 | 0.98 | SIRT6 (1.00) | SIRT6ADRB1MAPTHTR7HTR1A | |
| Hydrochloric Acid SCHEMBL1814630 | 0.96 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| Hydrogen Sulfide SCHEMBL28002215 | 0.96 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL6151805 | 0.96 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL27980887 | 0.93 | SIRT6 (0.90) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL942183 | 0.92 | SIRT6 (0.87) | SIRT6ADRB1MAPTHTR7HTR1A | |
| Hydrochloric Acid SCHEMBL7984519 | 0.90 | SIRT6 (0.84) | SIRT6ADRB1MAPTHTR7HTR1A | |
| Propane SCHEMBL27412411 | 0.90 | SIRT6 (0.84) | SIRT6ADRB1MAPTHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5541287-A | DIAGNOSIS USING CYCLIC TRIPEPTIDES WITH NITROBENZYL 1,4,7,10-TETRAAZACYCLODODECANE-N,N*,N**,N***TETRAACETIC ACID BIOTIN CONJUGATE FORMED BY ALKYLATION AND MULTISTAGE PROCESS | NEORX CORPORATION (US) | 1996-07-30 | — | — | US | claimed |
| US-8318134-B2 | Responsive paramagnetic MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2012-11-27 | — | — | US | disclosed |
| US-8318134-B2 | Responsive paramagnetic MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2012-11-27 | — | — | US | disclosed |
| US-8318134-B2 | Responsive paramagnetic MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2012-11-27 | — | — | US | disclosed |
| EP-1469890-B1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2011-08-10 | — | — | EP | disclosed |
| EP-1469890-B1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2011-08-10 | — | — | EP | disclosed |
| EP-2298362-A1 | Responsive paramagnetic MRI contrast agents | Bracco Imaging S.p.A (IT) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298362-A1 | Responsive paramagnetic MRI contrast agents | Bracco Imaging S.p.A (IT) | 2011-03-23 | — | — | EP | disclosed |
| US-20090234221-A1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2009-09-17 | — | — | US | disclosed |
| US-20090234221-A1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2009-09-17 | — | — | US | disclosed |
| US-20090234221-A1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2009-09-17 | — | — | US | disclosed |
| US-7524483-B2 | Responsive paramagnetic MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2009-04-28 | — | — | US | disclosed |
| US-7524483-B2 | Responsive paramagnetic MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2009-04-28 | — | — | US | disclosed |
| US-7524483-B2 | Responsive paramagnetic MRI contrast agents | BRACCO IMAGING S.P.A. (IT) | 2009-04-28 | — | — | US | disclosed |
| US-20050191243-A1 | Responsive paramagnetic mri contrast agents | BRACCO IMAGING S.P.A. (IT) | 2005-09-01 | — | — | US | disclosed |
| CN-1069027-A | Aminocarboxylate ligands with substituted aromatic amide moieties | SQUIBB & SONS INC (US) | 1993-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234221-A1 | RESPONSIVE PARAMAGNETIC MRI CONTRAST AGENTS | MYT1, PRTN3, CECR2 | SIRT6 2480/4885ADRB1 2963/4885MAPT 915/4885 |
| US-20050191243-A1 | Responsive paramagnetic mri contrast agents | MYT1, PRTN3, CECR2 | SIRT6 2480/4885ADRB1 2963/4885MAPT 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.